Hospital initiative shortens COVID-19 treatment delays
-
By
-
Matthew Solan
-
October 22, 2026
-
4 min
Clinical Scorecard: COVID-19 treatment initiation time decreases after hospital initiative
At a Glance
Category | Detail |
|---|---|
Condition | COVID-19 in hospitalized adults, most of whom had mild-to-moderate illness and were at high risk for progression to severe disease. |
Key Mechanisms | The quality improvement initiative included baseline audit-feedback sessions, point-of-care resources, follow-up workshops, and institutional action plans. Baseline surveys identified difficulty classifying illness severity and gaps in guideline knowledge as frequently reported barriers. |
Target Population | Hospitalized adults aged 18 years or older with a positive SARS-CoV-2 antigen or molecular test. |
Care Setting | Four health care systems participating in a quasi-experimental pre-post study conducted from December 2024 through June 2025. |
Key Highlights
Median time to COVID-19 treatment initiation decreased from 12 hours to seven hours after the initiative.
Guideline-concordant treatment was documented in 97% of patients before the intervention and 95% afterward.
Baseline and follow-up chart audits each included 150 hospitalized adults.
Remdesivir monotherapy was the most frequently documented regimen, increasing from 65% to 69%.
Researchers reported improvements in health care professionals’ knowledge, competence, and confidence following the educational sessions.
Action plans most often prioritized treatment-guideline awareness and updates to institutional protocols.
The pre-post study design limits attribution of the observed changes solely to the intervention.
Guideline-Based Recommendations
Diagnosis
Study eligibility required patients to be aged 18 years or older and have a positive SARS-CoV-2 antigen or molecular test.
Most patients had mild-to-moderate COVID-19 and were at high risk for progression to severe disease.
Difficulty classifying illness severity was the most frequently reported barrier in the baseline survey, identified by 48% of respondents.
Management
Guideline-concordant treatment was documented in 97% of patients before the intervention and 95% afterward.
Remdesivir monotherapy was the most frequently documented regimen in both study phases.
Correct identification that remdesivir could be used regardless of renal impairment, including in patients receiving dialysis, increased from 27% to 46% during the initial sessions.
During the follow-up sessions, correct recommendation of remdesivir for a patient receiving dialysis increased from 25% to 100%.
Monitoring & Follow-up
Baseline and follow-up chart audits each included 150 hospitalized adults.
Follow-up workshops involving 20 health care professionals occurred two to five months after the initial sessions.
Patient chart audits and professional surveys were used to evaluate practice changes and educational outcomes.
The source does not report whether the observed improvements persisted beyond the follow-up period.
Risks
Among 63 baseline survey respondents, 48% identified difficulty classifying illness severity as a barrier to timely care.
Gaps in knowledge of treatment guidelines were reported by 41% of baseline survey respondents.
The study used a quasi-experimental pre-post design, limiting attribution of the observed changes solely to the intervention.
Clinical outcomes such as mortality and length of stay were not reported.
Although researchers described improvements as significant, the source does not provide P values or confidence intervals.
Patient & Prescribing Data
Baseline and follow-up chart audits each included 150 hospitalized adults aged 18 years or older with positive SARS-CoV-2 antigen or molecular tests. Most patients had mild-to-moderate COVID-19 and were at high risk for progression to severe disease.
Median time to treatment initiation decreased from 12 hours before the initiative to seven hours afterward. Guideline-concordant treatment was documented in 97% of patients before the intervention and 95% afterward.
Remdesivir monotherapy increased from 65% to 69%, while nirmatrelvir/ritonavir monotherapy decreased from 21% to 18%. Treatment with remdesivir plus corticosteroids increased from 7% to 10%, while treatment with remdesivir, corticosteroids, and an immunomodulatory agent decreased from 3% to 2%.
Among 63 baseline survey respondents, difficulty classifying illness severity and gaps in guideline knowledge were reported by 48% and 41%, respectively.
Initial audit-feedback sessions involved 90 health care professionals. Follow-up workshops involved 20 professionals, while 27 respondents completed the follow-up survey; these are distinct participation counts reported in the source. Among the follow-up survey respondents, 70% reported improved hospital performance in identifying risk factors, selecting therapies, and initiating treatment promptly.
Clinical Best Practices
The initiative combined audit-feedback sessions, point-of-care resources, follow-up workshops, and institutional action plans.
Initial sessions allowed participating health care professionals to review baseline findings and develop institutional action plans.
Action plans most often prioritized treatment-guideline awareness, identified by 71%, and institutional protocol updates, identified by 36%.
At follow-up, guideline-awareness efforts and institutional protocol updates were reported as successfully implemented by 40% and 30% of respondents, respectively.
Follow-up chart audits and professional surveys were used to evaluate practice changes and educational outcomes.
High confidence in overcoming barriers to early treatment increased from 35% to 100% during the follow-up sessions.
Related Resources & Content
Source Material
Hospital initiative shortens COVID-19 treatment delays. IDSA Reporter. Published October 22, 2026.
Supplemental Related Resources
These resources provide related clinical guidance or evidence. They were selected separately and were not part of the source material supplied for this derivative.
IDSA Guidelines on the Treatment and Management of Patients With COVID-19. Infectious Diseases Society of America.
COVID-19 Treatment Clinical Care for Outpatients. Centers for Disease Control and Prevention.
Clinical Course: Progression, Management, and Treatment. Centers for Disease Control and Prevention.
Martínez-Suárez A, Salamanca-Rivera E, Cordero-Ramos J, Rodríguez-Baño J, Retamar-Gentil P. Effectiveness and safety of a prospective audit and feedback-based antimicrobial stewardship program in hospitalized COVID-19 patients: a quasi-experimental before-and-after study. Front Pharmacol. 2026;17:1662195. doi:[10.3389/fphar.2026.1662195](https://doi.org/10.3389/fphar.2026.1662195).
Carr AL, et al. Remdesperate for Stewardship: Impact of a Remdesivir Stewardship Strategy on the Care of Patients With COVID-19 Admitted to a Community Teaching Hospital. Open Forum Infect Dis. 2022;9(suppl 2):ofac492.770.
Based on findings from:
Hospital initiative shortens COVID-19 treatment delays
Matthew Solan. Idsa Reporter, 2026.
https://idsareporter.com/issues/2026/october-2026/hospital-initiative-shortens-covid19-treatment-delays/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.